Inhibition of LIFR Blocks Adiposity-Driven Endometrioid Endometrial Cancer Growth

Logan Blankenship, Uday P. Pratap, Xue Yang, Zexuan Liu, Kristin A. Altwegg, Bindu Santhamma, Kumaraguruparan Ramasamy, Swapna Konda, Yidong Chen, Zhao Lai, Siyuan Zheng, Gangadhara R Sareddy, Philip T Valente, Edward R. Kost, Hareesh B. Nair, Rajeshwar R. Tekmal, Ratna K. Vadlamudi, Suryavathi Viswanadhapalli

Research output: Contribution to journalArticlepeer-review

Abstract

Endometrial cancer (EC) is the fourth most common cancer in women, and half of the endometrioid EC (EEC) cases are attributable to obesity. However, the underlying mechanism(s) of obesity-driven EEC remain(s) unclear. In this study, we examined whether LIF signaling plays a role in the obesity-driven progression of EEC. RNA-seq analysis of EEC cells stimulated by adipose conditioned medium (ADP-CM) showed upregulation of LIF/LIFR-mediated signaling pathways including JAK/STAT and interleukin pathways. Immunohistochemistry analysis of normal and EEC tissues collected from obese patients revealed that LIF expression is upregulated in EEC tissues compared to the normal endometrium. Treatment of both primary and established EEC cells with ADP-CM increased the expression of LIF and its receptor LIFR and enhanced proliferation of EEC cells. Treatment of EEC cells with the LIFR inhibitor EC359 abolished ADP-CM induced colony formation andcell viability and decreased growth of EEC organoids. Mechanistic studies using Western blotting, RT-qPCR and reporter assays confirmed that ADP-CM activated LIF/LIFR downstream signaling, which can be effectively attenuated by the addition of EC359. In xenograft assays, co-implantation of adipocytes significantly enhanced EEC xenograft tumor growth. Further, treatment with EC359 significantly attenuated adipocyte-induced EEC progression in vivo. Collectively, our data support the premise that LIF/LIFR signaling plays an important role in obesity-driven EEC progression and the LIFR inhibitor EC359 has the potential to suppress adipocyte-driven tumor progression.

Original languageEnglish (US)
Article number5400
JournalCancers
Volume14
Issue number21
DOIs
StatePublished - Nov 2022

Keywords

  • EC359
  • endometrioid endometrial cancer
  • leukemia inhibitory factor
  • leukemia inhibitory factor receptor
  • obesity
  • RNA-seq

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint

Dive into the research topics of 'Inhibition of LIFR Blocks Adiposity-Driven Endometrioid Endometrial Cancer Growth'. Together they form a unique fingerprint.

Cite this